contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2510-expres2ion-biotechnologies-ascelia-pharma-og-aktier-med-friis

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Biotekdirektør smager egen medicin: Deltager i klinisk forsøg med coronavaccine Adm. direktør Bent U. Frandsen fra biotekselskabet Expres2ion er blandt de 3000 frivillige, der har meldt sig til at deltage i vaccineselskabet Bavarian Nordics fase 3-forsøg med deres fælles udviklede covid-19 vaccine. Tidligere på ugen fik topchefen et vaccinestik. Jeg synes det er for cool!, men også meget tilfældigt med selve udvælgelsen. Du kan læse hele Bents egen kommentar her:                   linkedin.com              Bent Frandsen on LinkedIn: #covid19vaccine #clinicalstudy #phase3 | 16 comments    👍🏻 GETTING A TASTE OF MY OWN MEDICINE 👏🏻  This week I got a shot of COVID-19 vaccine in the ABNCoV2 Phase 3 clinical study in Denmark. How often do... 16 comments on LinkedIn

ExpreS2ion Biotechnologies offentliggjorde i morges deres tal for deres Q3 rapport, hvor de i den forbindelse afholdte en præsentation af netop denne for 2022. Jeg synes det var et spændende event, hvor de både nåede ind på deres resultater, mens de også tog et dybere kig på deres omkostninger. Dernæst nåede de ogå omkring deres Covid-19 vaccinekandidat og tog et kig på markedet som helhed. Afsluttende snakkede de desuden om nogle af de andre produktkandidater, som de har i deres pipeline

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen. English:  ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34% of. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

Dagens aktienyheder med ExpreS2ion Biotechnologies, Ascelia Pharma og Aktier med Friis

ExpreS2ion Biotechnologies satte i g&#xe5;r dato p&#xe5;, hvorn&#xe5;r de gennemf&#xf8;rer det omvendte aktiesplit efter, at det blev godkendt p&#xe5; en ekstraordin&#xe6;r generalforsamling i mandags. Sidste handelsdag f&#xf8;r det omvendte aktiesplit er den 29. oktober og dermed vil kursen den 30. oktober afspejle det gennemf&#xf8;rte split. Aktien splitter 1 til 40, og antallet af aktier udest&#xe5;ende vil derefter v&#xe6;re p&#xe5; ca. 2,1 mio. Som aktion&#xe6;r skal man ikke foretage sig noget p&#xe5; baggrund af aktiesplittet, og dette &#xe6;ndrer ikke noget fundamentalt ved aktien og den samlede v&#xe6;rdis&#xe6;tning. Det omvendte aktiesplit &#xe6;ndrer heller ikke noget p&#xe5; de igangv&#xe6;rende TO 10 og TO 11-warrantsprogrammer. L&#xe6;s mere her: <a href="https://www.inderes.dk/releases/expres2ion-biotechnologies-the-board-of-directors-of-expres2ion-biotech-holding-ab-publ-has-resolved-on-the-record-date-for-the-reverse-share-split" target="_blank" rel="noopener">https://www.inderes.dk/releases/expres2ion-biotechnologies-the-board-of-directors-of-expres2ion-biotech-holding-ab-publ-has-resolved-on-the-record-date-for-the-reverse-share-split</a> Ascelia Pharma deltog i g&#xe5;r p&#xe5; den &#xe5;rlige &#x201d;American Society of Nephrology Kidney Week&#x201d;-konference 2024 i San Diego, USA. Ascelia Pharma pr&#xe6;senterede abstracts fra sit multicenter &#x201d;SPARKLE&#x201d; studiet. L&#xe6;s mere her: <a href="https://www.inderes.dk/releases/ascelia-pharma-presents-late-breaking-abstract-on-sparkle-data-at-the-american-society-of-nephrology-kidney-week-congress-2024" target="_blank" rel="noopener">https://www.inderes.dk/releases/ascelia-pharma-presents-late-breaking-abstract-on-sparkle-data-at-the-american-society-of-nephrology-kidney-week-congress-2024</a> I dagens Aktier med Friis kl. 12:00 ser vi tilbage p&#xe5; en uge, hvor markedet prisede sig l&#xe6;ngere ind i Trump som pr&#xe6;sident og dermed en &#xf8;get sandsynlighed for en no landing-&#xf8;konomi. Tilmeld dig og stil sp&#xf8;rgsm&#xe5;l om markedet generelt eller enkeltaktier her: <a href="https://www.inderes.dk/videos/aktier-med-friis-uge-43-2024">https://www.inderes.dk/videos/aktier-med-friis-uge-43-2024</a> 
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en Digital IR/Corporate Visibility abonnementsaftale.
/Kasper Lihn kl. 09:17 d. 25/10-2024

Stay up to date with our newsletter